 |
 |
 |
 |
 |
 |
 |
 |
 |
  |
||||||||
Avontec is a biopharmaceutical company addressing large-market indication areas with product candidates derived from its unique and powerful decoy oligonucleotide platform technology. Avontec’s unique approach makes transcription factors into “drugable” targets.
Avontec’s lead drug candidates AVT-01 and AVT-02 are in Phase 2a clinical studies in asthma and psoriasis. In pilot studies these development candidates showed excellent safety and had demonstrable effects on relevant endpoints.
